Results 131 to 140 of about 1,456,287 (196)

Complete Pathological Response to Crizotinib in a Patient with ALK-rearranged Lung Adenocarcinoma. [PDF]

Clin Lung Cancer, 2020
Mattar MS, Chang J, Benayed R, Halpenny D, Powers A, Kleiner DE, Drilon A, Kris MG.   +7 more
europepmc   +1 more source

Clinico-pathological features and pathological Complete Responses (pCR) to primary chemotherapy (PC)

European Journal of Cancer Supplements, 2008
A. Ferro, R. Triolo, A. Caldara, O. Caffo, M. Barbareschi, M. Pellegrini, S. Mussari, F. Gasperetti, G. Berlanda, E.N.Z.O. Galligioni   +9 more
openaire   +1 more source

GSTP1 expression predicts poor pathological complete response to neoadjuvant chemotherapy in ER-negative breast cancer [PDF]

ミヤケ, トモヒロ, 三宅, 智博
core  

Occult breast cancer with pathological complete response to neoadjuvant chemotherapy

Asian Journal of Surgery
Ningning Ren, Shuo Liu, Peng Shi, Xingsong Tian   +3 more
openaire   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

Gastric Remnant Cancer: Complete Pathological Response - Case report

European Journal of Surgical Oncology, 2022
Background: Remnant gastric cancer (RGC) refers to carcinoma of the residual stomach occurring after gastrectomy. With an incidence of 1-7%, it is believed to have a different disease mechanism and a poorer prognosis than primary gastric cancer (PGC ...
Johnn Henry Herrera Kok, Antonio Álvarez Martínez, Manuela Pedraza Lorenzo, María Concepción Álvarez Cañas, María Inmaculada Matanza Rodríguez, Luis Carlos Martínez Blanco, María Victoria Diago Santamaría   +6 more
openaire   +2 more sources

P162: Is complete pathological response truly a complete response?!

European Journal of Surgical Oncology, 2020
Bushra Rehman, Nida Javaid, Mohammad Zulqarnain Chaudhary, Mohammad Asad Parvaiz, Amina Khan   +4 more
openaire   +2 more sources

Pathological complete response in breast cancer

The Lancet, 2015
www.thelancet.com Vol 385 January 10, 2015 113 Pathological complete response could better predict survival for women with hormone-receptor-negative breast cancer and with HER2-positive breast cancer treated with HER2 antagonists, but does not predict long-term outcome for hormone-positive or histologically low-grade tumours.
Alberto, Ocana, Bostjan, Seruga, Eitan, Amir   +2 more
  +7 more sources

Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis.

Lancet, The, 2014
P. Cortazar, Lijun Zhang, M. Untch, K. Mehta, J. Costantino, N. Wolmark, H. Bonnefoi, D. Cameron, L. Gianni, P. Valagussa, S. Swain, Tatiana M. Prowell, S. Loibl, L. Wickerham, J. Bogaerts, J. Baselga, C. Perou, G. Blumenthal, J. Blohmer, E. Mamounas, J. Bergh, V. Semiglazov, R. Justice, H. Eidtmann, S. Paik, M. Piccart, R. Sridhara, P. Fasching, L. Slaets, Shenghui Tang, B. Gerber, C. Geyer, R. Pazdur, N. Ditsch, P. Rastogi, W. Eiermann, G. Minckwitz   +36 more
semanticscholar   +3 more sources

Complete pathological response in rectal cancer utilising novel treatment strategies for neo-adjuvant therapy: A systematic review.

European Journal of Surgical Oncology, 2021
BACKGROUND Locally advanced rectal cancer is routinely treated with neo-adjuvant long course chemoradiotherapy or short course radiotherapy, followed by total mesorectal excision. Not all patients respond to this treatment and there has been an emergence
K. Wilson, M. Flood, V. Narasimhan, T. Pham, S. Warrier, R. Ramsay, M. Michael, A. Heriot   +7 more
semanticscholar   +1 more source